MK-3207

CAS No. 957118-49-9

MK-3207( MK3207 | MK 3207 )

Catalog No. M16837 CAS No. 957118-49-9

A highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 323 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MK-3207
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay.
  • Description
    A highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay; displays >50000-fold selectivity in a panel of 160 enzymes, receptors, channels, and 65-fold more potent than telcagepant; orally bioavailable.
  • In Vitro
    MK-3207 (0.3, 0.6, 1.1, 2.3, 4.5, 9.0 nM; 30 min) potently blocks human α-CGRP-stimulated cAMP responses in human CGRP receptor-expressing HEK293 cells. Cell Viability Assay Cell Line:HEK293 cells (stably expressing human CLR/RAMP1)Concentration:0.3, 0.6, 1.1, 2.3, 4.5, 9.0 nM Incubation Time:30 min (pre-treat)Result:Blocked human α-CGRP-stimulated cAMP responses with an IC50 value of 0.12 nM.
  • In Vivo
    MK-3207 (0.3, 0.6, 2.1, 9.1, 21.2, 60.6 μg/kg; i.v.; single) inhibits CIDV in rhesus monkeys with EC50 and Emax values of approximately 0.8 nM and 81%.MK-3207 (10 mg/kg; p.o.; single) shows the CSF/plasma ratio is 2 to 3%. Animal Model:Adult rhesus monkeys (4.8-12.7 kg; capsaicin-induced).Dosage:0.3, 0.6, 2.1, 9.1, 21.2, 60.6 μg/kg Administration:Intravenous injection; single.Result:Resulted in an exposure-dependent decrease in capsaicin-induced dermal vasodilation in the rhesus monkey forearm.Animal Model:Adult rhesus monkeys (4.8-12.7 kg).Dosage:10 mg/kg Administration:Oral administration; single.Result:Exhibited the CSF/plasma ratio was 2 to 3%, however the CSF/plasma ratio was approximately 30% of the unbound fraction (9.4%) in plasma.
  • Synonyms
    MK3207 | MK 3207
  • Pathway
    GPCR/G Protein
  • Target
    CGRP Receptor
  • Recptor
    CGRP Receptor
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    957118-49-9
  • Formula Weight
    557.5905
  • Molecular Formula
    C31H29F2N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    C1CCC2(C1)C(=O)N(C(CN2)C3=CC(=CC(=C3)F)F)CC(=O)NC4=CC5=C(CC6(C5)C7=C(NC6=O)N=CC=C7)C=C4
  • Chemical Name
    6,9-Diazaspiro[4.5]decane-9-acetamide, 8-(3,5-difluorophenyl)-10-oxo-N-[(2R)-1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl]-, (8R)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bell IM, et al. ACS Med Chem Lett. 2010 Jan 12;1(1):24-9. 2. Salvatore CA, et al. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60. 3. Li CC, et al. Br J Clin Pharmacol. 2015 May;79(5):831-7.
molnova catalog
related products
  • Erenumab

    Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attacks.

  • Ubrogepant

    Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.

  • Calcitonin salmon

    Calcitonin salmon, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.